Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial

Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide)…

RRMM Trial Testing Safety, Efficacy of TAK-169 Therapy Doses First Patient

The first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of the CD38-targeting therapy TAK-169…